Lower Ratings Shake Morale at NIH

WASHINGTON--One day last fall NIH lost one-half of its "outstanding" scientist administrators. Nobody left, and there was no immediate drop in the amount or quality of work being performed on the Bethesda campus. The change was strictly on paper, a result of a 1986 decision by the Reagan administration to reduce the number of “outstanding” performance ratings given to senior executives throughout the government. But NIH Director James Wyngaarden and others feel the policy delivers

Written byJeffrey Mervis
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

But NIH Director James Wyngaarden and others feel the policy delivers a devastating blow to morale at an agency already struggling to staunch the flow of top scientists to universities and private industry. And a congressional oversight committee recently took top Health and Human Services Department officials to task for their "grotesquely unfair" actions and their "insensitivity" toward federal workers.

NIH historically has given the highest possible performance rating to a large proportion "as much as 80 percent"of its top administrators and scientists. Two years ago the Office of Personnel Management, in a decision embraced by HHS Secretary Otis Bowen, issued new guidelines to reverse what Bowen has called "rapid grade creep" in the evaluation of federal workers. OPM decided that 35 percent was a more reasonable figure; any agency that planned to classify as outstanding a higher percentage of its senior administrators would need to justify its decision.

The ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies